S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
OTCMKTS:DTCFF

Defence Therapeutics - DTCFF Stock Forecast, Price & News

$3.79
0.00 (0.00%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.79
▼
$3.79
50-Day Range
$1.70
▼
$3.79
52-Week Range
$1.12
▼
$3.79
Volume
N/A
Average Volume
533 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DTCFF stock logo

About Defence Therapeutics (OTCMKTS:DTCFF) Stock

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Receive DTCFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DTCFF Stock News Headlines

February 6, 2023 | finance.yahoo.com
RETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
February 3, 2023 | finance.yahoo.com
Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
February 7, 2023 | Wall Street Watch Dogs (Ad)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
February 1, 2023 | finanznachrichten.de
Defence Therapeutics Inc.: Breakthrough Results: Defence's Novel AccuTOX Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors
January 31, 2023 | uk.finance.yahoo.com
Defence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES
January 31, 2023 | finance.yahoo.com
Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances
January 25, 2023 | finanznachrichten.de
Defence Therapeutics Inc.: Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated
January 25, 2023 | finanznachrichten.de
Defence Therapeutics Inc.: mRNA with Defence's Accum Program Has Been Initiated
February 7, 2023 | Wall Street Watch Dogs (Ad)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
January 25, 2023 | finanznachrichten.de
Defence Therapeutics Inc.: Defence Accum Accepted Us Patent to Bolster Its Vaccine Platform Technology IP
January 24, 2023 | finanznachrichten.de
Defence Therapeutics Inc.: Defence Therapeutics Completes Fully-Subscribed Debenture Financing of $2,355,000
January 24, 2023 | finance.yahoo.com
Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated
January 24, 2023 | uk.finance.yahoo.com
DEFENCE’S MELANOMA TARGETED VACCINE A1-REPROGRAMMED MSC (ARM) CELL POTENCY VALIDATED
January 23, 2023 | uk.finance.yahoo.com
Defence Therapeutics Inc.: DEFENCE TO PRESENT AT THE 9TH ANNUAL IMMUNO-ONCOLOGY 360º SUMMIT IN NEW-YORK FEBRUARY 7-10, 2023
January 23, 2023 | finance.yahoo.com
RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
January 18, 2023 | seekingalpha.com
Defence Therapeutics to get US patent linked to vaccine technology
January 16, 2023 | finance.yahoo.com
Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP
January 10, 2023 | uk.finance.yahoo.com
Defence Therapeutics Inc.: mRNA WITH DEFENCE’S ACCUMTM PROGRAM HAS BEEN INITIATED
January 10, 2023 | finance.yahoo.com
mRNA with Defence's Accum(TM) Program Has Been Initiated
December 20, 2022 | uk.finance.yahoo.com
Defence Therapeutics Inc.: BREAKTHROUGH RESULTS: DEFENCE’S NOVEL ACCUTOXTM INTRANASAL REDUCED 50% OF CANCER NODULES ON ANIMALS WITH LUNG TUMORS
December 20, 2022 | finance.yahoo.com
Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors
December 15, 2022 | uk.finance.yahoo.com
Defence Therapeutics Inc.: DEFENCE'S mRNA WITH ACCUMTM FOR CANCER VACCINES UPDATE
December 9, 2022 | finance.yahoo.com
Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors
December 6, 2022 | finance.yahoo.com
Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies
November 23, 2022 | finanznachrichten.de
Defence Therapeutics Inc.: Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer
November 23, 2022 | finance.yahoo.com
Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer
November 16, 2022 | finance.yahoo.com
Defence Therapeutics Completes Fully-Subscribed Debenture Financing of $2,355,000
See More Headlines
Receive DTCFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DTCFF
CUSIP
N/A
CIK
N/A
Web
defencetherapeutics.com
Phone
514 947 2272
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Sebastien Plouffe (Age 50)
    CEO, Pres & Director
    Comp: $65.47k
  • Mr. Patrick Joseph Meagher C.A. (Age 36)
    CPA, CA, CPA, CFO & Director
    Comp: $52.38k
  • Dr. Moutih Rafei Ph.D. (Age 40)
    VP of R&D and Director
  • Dr. Simon Beaudoin (Age 38)
    Chief Technical Science Officer
  • Ms. Carrie Cesarone (Age 57)
    Corp. Sec.

Key Competitors

View All Competitors













DTCFF Stock - Frequently Asked Questions

How have DTCFF shares performed in 2023?

Defence Therapeutics' stock was trading at $1.70 at the beginning of 2023. Since then, DTCFF shares have increased by 122.9% and is now trading at $3.79.
View the best growth stocks for 2023 here.

What is Defence Therapeutics' stock symbol?

Defence Therapeutics trades on the OTCMKTS under the ticker symbol "DTCFF."

How do I buy shares of Defence Therapeutics?

Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Defence Therapeutics' stock price today?

One share of DTCFF stock can currently be purchased for approximately $3.79.

How can I contact Defence Therapeutics?

The official website for the company is defencetherapeutics.com. The company can be reached via phone at 514 947 2272.

This page (OTCMKTS:DTCFF) was last updated on 2/7/2023 by MarketBeat.com Staff